Načítá se...
SB8: A Bevacizumab Biosimilar
SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy vol...
Uloženo v:
| Vydáno v: | Target Oncol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7733936/ https://ncbi.nlm.nih.gov/pubmed/33206282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00776-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|